Objective:To investigate the role of18F-FDG SPECT/PET in the diagnosis and initial staging of lymphoma.Methods:A retrospective analysis was carried out on 48 patients in Haikou Hospital from January 2015 to June 2018,...Objective:To investigate the role of18F-FDG SPECT/PET in the diagnosis and initial staging of lymphoma.Methods:A retrospective analysis was carried out on 48 patients in Haikou Hospital from January 2015 to June 2018,who were eventually pathologically diagnosed with lymphoma and had undergone18F-FDG SPECT/PET before definite diagnosis.(1)Patients were divided into Hodgkin's lymphoma group,diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group according to Pathological classification;and were divided into nodal lymphoma group and extranodal lymphoma group according to the presence of invasion to the tissues beyond lymph node;and were divided into stage I+Ⅱgroup and stageⅢ+IV group according to clinical Ann Arbor staging.The diagnostic consistencies of18F-FDG SPECT/PET and conventional imaging(CI)in each group were calculated,the T/N ratios of the lymphoma lesion were analyzed as well.(2)Clinical Ann Arbor staging,SPECT/PET staging and CI staging were performed in 48 patients,respectively.Then the efficacy of SPECT/PET staging and CI staging was compared,and the consistency of SPECT/PET staging and clinical Ann Arbor staging was compared as well.Results:(1)In this study,the diagnostic consistent rates of18F-FDG SPECT/PET and CI were 45.8%(22/48)and 16.6%(8/48),respectively(χ2=9.503,P=0.002<0.01).(2)The diagnostic consistent rate of18F-FDG SPECT/PET in diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group was higher than that of CI(P<0.05).There was no statistical significance between the diagnostic consistent rates of18F-FDG SPECT/PET in the Hodgkin's lymphoma group,diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group(χ2=1.067,P=0.448>0.05).(3)The diagnostic consistent rates of18F-FDG SPECT/PET in nodal group and extranodal group were 100.0%(19/19)and 21.1%(4/19)(χ2=24.783,P=0.000<0.01),respectively.(4)The diagnostic consistent rates of18F-FDG SPECT/PET and CI were 25%(2/8)and 0(0/8)in lymphoma with early stage(stage I+Ⅱgroup)(χ2=2.268,P=0.131>0.05),and 50%(20/40)and 20%(8/40)in lymphoma with late stage(stageⅢ+IV group)(χ2=7.912,P=0.002<0.01),respectively.(5)There was no statistical significance in T/N ratios of lymphoma lesions between different pathological groups,between nodal group and extranodal group,or between the stage I+Ⅱgroup and the stageⅢ+IV group(P>0.05).(6)The total consistent rates of18F-FDG SPECT/PET and CI for initial lymphoma staging were 79.2%(38/45)and 64.4%(31/48)(χ2=18.774,P=0.000<0.01).SPECT/PET staging was well consistent with clinical Ann Arbor staging in initial lymphoma staging(Kappa=0.696,P=0.000<0.01).Conclusion:The research has showed that the consistent rates of18F-FDG SPECT/PET in the diagnosis and initial staging of lymphoma are relatively high,and18F-FDG SPECT/PET plays an important role in the diagnosis and initial staging of lymphoma.展开更多
Heart failure is a dynamic condition with high morbidity and mortality and its prognosis should be reassessed frequently, particularly in patients for whom critical treatment decisions may depend on the results of pro...Heart failure is a dynamic condition with high morbidity and mortality and its prognosis should be reassessed frequently, particularly in patients for whom critical treatment decisions may depend on the results of prognostication. In patients with heart failure, nuclear cardiology techniques are useful to establish the etiology and the severity of the disease, while fewer studies have explored the potential capability of nuclear cardiology to guide cardiac resynchronization therapy(CRT) and to select patients for implantable cardioverter defibrillators(ICD). Left ventricular synchrony may be assessed by radionuclide angiography or gated singlephoton emission computed tomography myocardial perfusion scintigraphy. These modalities have shown promise as predictors of CRT outcome using phase analysis. Combined assessment of myocardial viability and left ventricular dyssynchrony is feasible using positron emission tomography and could improve conventional response prediction criteria for CRT. Preliminary data also exists on integrated positron emission tomography/computed tomography approach for assessing myocardial viability, identifying the location of biventricular pacemaker leads, and obtaining left ventricular functional data, including contractile phase analysis. Finally, cardiac imaging with autonomic radiotracers may be useful in predicting CRT response and for identifying patients at risk for sudden cardiac death, therefore potentially offering a way to select patients for both CRT and ICD therapy. Prospective trials where imaging is combined with image-test driven therapy are needed to better define the role of nuclear cardiology for guiding device therapy in patients with heart failure.展开更多
基金National Natural Science Foundation of China(No.81960556)Hainan Health and Family Planning Industry Research Project(No.18A200179).
文摘Objective:To investigate the role of18F-FDG SPECT/PET in the diagnosis and initial staging of lymphoma.Methods:A retrospective analysis was carried out on 48 patients in Haikou Hospital from January 2015 to June 2018,who were eventually pathologically diagnosed with lymphoma and had undergone18F-FDG SPECT/PET before definite diagnosis.(1)Patients were divided into Hodgkin's lymphoma group,diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group according to Pathological classification;and were divided into nodal lymphoma group and extranodal lymphoma group according to the presence of invasion to the tissues beyond lymph node;and were divided into stage I+Ⅱgroup and stageⅢ+IV group according to clinical Ann Arbor staging.The diagnostic consistencies of18F-FDG SPECT/PET and conventional imaging(CI)in each group were calculated,the T/N ratios of the lymphoma lesion were analyzed as well.(2)Clinical Ann Arbor staging,SPECT/PET staging and CI staging were performed in 48 patients,respectively.Then the efficacy of SPECT/PET staging and CI staging was compared,and the consistency of SPECT/PET staging and clinical Ann Arbor staging was compared as well.Results:(1)In this study,the diagnostic consistent rates of18F-FDG SPECT/PET and CI were 45.8%(22/48)and 16.6%(8/48),respectively(χ2=9.503,P=0.002<0.01).(2)The diagnostic consistent rate of18F-FDG SPECT/PET in diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group was higher than that of CI(P<0.05).There was no statistical significance between the diagnostic consistent rates of18F-FDG SPECT/PET in the Hodgkin's lymphoma group,diffuse large B cell lymphoma group and other non-Hodgkin's lymphoma group(χ2=1.067,P=0.448>0.05).(3)The diagnostic consistent rates of18F-FDG SPECT/PET in nodal group and extranodal group were 100.0%(19/19)and 21.1%(4/19)(χ2=24.783,P=0.000<0.01),respectively.(4)The diagnostic consistent rates of18F-FDG SPECT/PET and CI were 25%(2/8)and 0(0/8)in lymphoma with early stage(stage I+Ⅱgroup)(χ2=2.268,P=0.131>0.05),and 50%(20/40)and 20%(8/40)in lymphoma with late stage(stageⅢ+IV group)(χ2=7.912,P=0.002<0.01),respectively.(5)There was no statistical significance in T/N ratios of lymphoma lesions between different pathological groups,between nodal group and extranodal group,or between the stage I+Ⅱgroup and the stageⅢ+IV group(P>0.05).(6)The total consistent rates of18F-FDG SPECT/PET and CI for initial lymphoma staging were 79.2%(38/45)and 64.4%(31/48)(χ2=18.774,P=0.000<0.01).SPECT/PET staging was well consistent with clinical Ann Arbor staging in initial lymphoma staging(Kappa=0.696,P=0.000<0.01).Conclusion:The research has showed that the consistent rates of18F-FDG SPECT/PET in the diagnosis and initial staging of lymphoma are relatively high,and18F-FDG SPECT/PET plays an important role in the diagnosis and initial staging of lymphoma.
文摘Heart failure is a dynamic condition with high morbidity and mortality and its prognosis should be reassessed frequently, particularly in patients for whom critical treatment decisions may depend on the results of prognostication. In patients with heart failure, nuclear cardiology techniques are useful to establish the etiology and the severity of the disease, while fewer studies have explored the potential capability of nuclear cardiology to guide cardiac resynchronization therapy(CRT) and to select patients for implantable cardioverter defibrillators(ICD). Left ventricular synchrony may be assessed by radionuclide angiography or gated singlephoton emission computed tomography myocardial perfusion scintigraphy. These modalities have shown promise as predictors of CRT outcome using phase analysis. Combined assessment of myocardial viability and left ventricular dyssynchrony is feasible using positron emission tomography and could improve conventional response prediction criteria for CRT. Preliminary data also exists on integrated positron emission tomography/computed tomography approach for assessing myocardial viability, identifying the location of biventricular pacemaker leads, and obtaining left ventricular functional data, including contractile phase analysis. Finally, cardiac imaging with autonomic radiotracers may be useful in predicting CRT response and for identifying patients at risk for sudden cardiac death, therefore potentially offering a way to select patients for both CRT and ICD therapy. Prospective trials where imaging is combined with image-test driven therapy are needed to better define the role of nuclear cardiology for guiding device therapy in patients with heart failure.
